Latest KFF Health News Stories
Hay aproximadamente 5.100 personas sin hogar en Washington, D.C., incluyendo aquellas en albergues temporales, según un conteo realizado a inicios de 2025.
Washington’s Homeless Hide in Plain Sight, Growing Sicker and Costing Taxpayers More
The White House says encampment sweeps have enhanced the capital, but city leaders estimate nearly 700 homeless people roam by day and bed down outdoors by night. Some have scattered to the suburbs while others avoid detection, making it hard for medical providers to care for them.
Out-of-Pocket Pain From High-Deductible Plans Means Skimping on Care
High-deductible health insurance plans are increasingly common, and many more enrollees will likely need to choose such plans for the coming year. For those with chronic conditions like diabetes, the gamble can mean compromised care and long-term consequences.
The Nation’s Largest Food Aid Program Is About To See Cuts. Here’s What You Should Know.
The federal government is making sweeping changes to SNAP, the program that helped feed about 42 million people in the U.S. last year. Here’s a breakdown of the changes to come and potential impacts.
Millions in US Live in Places Where Doctors Don’t Practice and Telehealth Doesn’t Reach
Nearly 3 million Americans live sicker, shorter lives in the hundreds of rural counties where doctor shortages are the worst and poor internet connections mean little or no access to telehealth services.
Este método, que podría llegar a tener gran utilidad en la era de los teléfonos inteligentes, es una aplicación que permite efectuar consultas médicas transfronterizas.
Schools Aren’t as Plugged In as They Should Be to Kids’ Diabetes Tech, Parents Say
With continuous glucose monitors, students with Type 1 diabetes no longer have to visit the school nurse for a finger prick. But some parents say it falls to them to keep an eye on blood sugar levels from home or work — even though they may not be able to quickly reach their child when something’s wrong.
Las escuelas no están conectadas como debieran a la tecnología para afrontar la diabetes infantil
En las escuelas, los maestros están atentos a las alarmas de los MCG de los teléfonos de los alumnos. Sin embargo, muchos dicen que no hay garantía de que un maestro pueda escucharlas.
Who Gets Obesity Drugs Covered by Insurance? In North Carolina, It Helps If You’re on Medicaid
GLP-1 agonist medications such as Ozempic accounted for 10% of the North Carolina state employee health plan’s prescription drug spending, so the state is no longer covering them for weight loss alone. Still, it did decide to cover them for Medicaid patients’ weight loss. A look inside the state’s coverage calculus.
¿Podrían los nuevos medicamentos para bajar de peso estar disponibles para todos?
Los medicamentos agonistas GLP-1, conocidos por los nombres comerciales Ozempic, Trulicity y Wegovy, han demostrado ser efectivos para la pérdida de peso y para el manejo de la diabetes tipo 2.
How Minnesota Figures Into the Presidential Politics of Insulin Prices
Minnesota led the way on insulin affordability, culminating in 2020 when Gov. Tim Walz signed a law going further to cut costs than other state laws. Now, former President Donald Trump and Vice President Kamala Harris are vying for support from people with diabetes.
Harris, alguna vez la voz de Biden sobre el aborto, tendría un enfoque abierto en temas de salud
Mientras los demócratas reconstruyen su candidatura presidencial a pocos meses de las elecciones, se esperaría que, de ser la nueva nominada, Harris adoptase una postura agresiva en apoyo al acceso al aborto y en otros temas controversiales de salud.
Harris, Once Biden’s Voice on Abortion, Would Take an Outspoken Approach to Health
If she grabs the baton from President Joe Biden to become the new presumptive Democratic presidential nominee, Kamala Harris would widely be expected to take an aggressive stance in support of abortion access — hitting former President Donald Trump on an issue that could undermine his chances of victory.
1st Biden-Trump Debate of 2024: What They Got Wrong, and Right
A debate marked by President Joe Biden’s faltering performance featured clashes over insulin costs, inflation, abortion, immigration, and Jan. 6.
Journalists Talk Cost of Weight Loss Drugs and Lack of Obesity Doctors to Manage Their Use
KFF Health News and California Healthline staff made the rounds on national and local media this week to discuss topical stories. Here’s a collection of their appearances.
High Price of Popular Diabetes Drugs Deprives Low-Income People of Effective Treatment
The makers of Ozempic and Mounjaro charge list prices of around $1,000 a month for the diabetes and obesity drugs, and insurers are reluctant to pick up the tab. Often, low-income patients have to resort to less effective treatments.
Personas de bajos ingresos no pueden recibir terapias efectivas contra la diabetes por el alto costo
La escasez de suministros y las barreras que ponen las aseguradoras para obtener esta poderosa clase de medicamentos, llamados agonistas de GLP-1, han dejado a muchas personas que viven con diabetes y obesidad sin los medicamentos que necesitan para mantenerse saludables.
Biden Is Right About $35 Insulin Cap but Exaggerates Prior Costs for Medicare Enrollees
Most Medicare enrollees likely were not paying a monthly average of $400 — as President Joe Biden stated — before the insulin cap took effect. However, because costs and other factors result in widely varying prices, some Medicare enrollees might have paid that much in a given month.
Programas de inteligencia artificial diagnostican retinopatía diabética en minutos
En medio de todo el revuelo en torno a la inteligencia artificial en la atención médica, la tecnología de exámenes de la vista está surgiendo como uno de los primeros casos de uso probados de diagnósticos basados en IA en un entorno clínico.
As AI Eye Exams Prove Their Worth, Lessons for Future Tech Emerge
With artificial intelligence in health care on the rise, eye screenings for diabetic retinopathy are emerging as one of the first proven use cases of AI-based diagnostics in a clinical setting.
